Ava­lyn rais­es $175M to test in­haler ver­sions of IPF med­i­cines in PhII tri­als

Last year
Financing

Ex­clu­sive: Pfiz­er, Gink­go sign R&D deal worth up to $331M to de­vel­op RNA drugs

Last year
Deals

Force­field Ther­a­peu­tics to start £35M Se­ries A in Oc­to­ber af­ter scoop­ing ex-No­var­tis ex­ec John Tsai as new CEO

Last year
People
Financing

Ab­b­Vie drops Cari­bou part­ner­ship on gene-edit­ed CAR-T ther­a­py

Last year
R&D
Cell/Gene Tx

San­doz, Pol­phar­ma score Eu­ro­pean ap­proval for first Tysabri biosim­i­lar for mul­ti­ple scle­ro­sis

Last year
FDA+

J&J shines spot­light on can­cer spe­cial­ty pro­fes­sion in new aware­ness and sup­port ef­fort

Last year
Marketing

J&J, IBM named in pro­posed class ac­tion law­suit fol­low­ing da­ta breach

Last year
Law

Cost-ef­fec­tive­ness of Mer­ck’s po­ten­tial hy­per­ten­sion drug will hinge on long-term da­ta, ICER says

Last year
Pharma

How Tik­Tok’s al­go­rithm and au­di­ences are fi­nal­ly con­vinc­ing Big Phar­ma to join

Last year
Pharma
Marketing

Mar­ket­ingRx roundup: Phar­ma in­dus­try rep drops in Gallup poll; Pfiz­er web­site re­veals not-yet-ap­proved drug name

Last year
Pharma
Marketing

Ready for it? Pfiz­er taps Kansas City Chiefs star Travis Kelce for lat­est Covid boost­er cam­paign

Last year
Marketing

Bris­tol My­ers joins As­traZeneca in agree­ing to drug price ne­go­ti­a­tion terms ahead of first dead­line

Last year
Pharma
Law

No­vo Nordisk forms car­diometa­bol­ic drug dis­cov­ery ac­cel­er­a­tor to get to re­search faster

Last year
Pharma

Pli­ant shares spike on ex­plorato­ry study re­sults of lead drug in chron­ic liv­er dis­ease

Last year
R&D

Pak­istan re­calls al­tered dose of Avastin; FDA re­jects Botanix gel

Last year
News Briefing

No­bel Prize win­ner Demis Has­s­abis talks about his vi­sion for Iso­mor­phic and AI’s fu­ture in biotech

Last year
People
AI

In­ter­cept to sell in $800M cash buy­out af­ter sec­ond NASH re­jec­tion sank hopes

Last year
Deals

Pox­el takes write­down on NASH drug as it con­tin­ues lay­offs, search for cash

Last year
People

Io­n­is plans NDA fil­ing for first in­de­pen­dent drug af­ter pos­i­tive da­ta read­out in rare ge­net­ic dis­or­der

Last year
R&D

Omega Ther­a­peu­tic­s' epige­nom­ic med­i­cines re­duce MYC ex­pres­sion by 55% in ear­ly study of can­cer pa­tients

Last year
R&D

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

Last year
Financing
Startups

Up­dat­ed: Roivant’s FcRn an­ti­body for au­toim­mune dis­ease shows ear­ly po­ten­tial in study with healthy sub­jects

Last year
R&D

Ace­sion clinch­es $47M in Se­ries B raise to ad­vance pre­clin­i­cal car­diac ar­rhyth­mia can­di­date through PhII

Last year
Financing

Take­da strikes $500M+ deal for Cal­i­for­nia biotech's ALS pro­gram

Last year
Deals
Pharma
First page Previous page 274275276277278279280 Next page Last page
A service from the Financial Times